West Pharmaceutical Services (WST) Retained Earnings (2009 - 2026)

West Pharmaceutical Services has disclosed Retained Earnings across 18 years of filings, most recently posting $4.5 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at $4.5 billion, up 11.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 11.03% YoY), and the FY2025 annual result was -$105.5 million, up 59.12% from the prior year.
• Retained Earnings came in at $4.5 billion for Q1 2026 at West Pharmaceutical Services, up from -$105.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $4.5 billion in Q1 2026 to a low of -$258.1 million in Q4 2024.
• The 5-year median for Retained Earnings is -$102.3 million (2025), against an average of $1.6 billion.
• Across the five-year window, Retained Earnings sank 111.38% in 2022 and surged 2196.31% in 2025, its largest moves.
• West Pharmaceutical Services' Retained Earnings stood at $3.0 billion in 2022, then plunged by 104.81% to -$143.8 million in 2023, then slumped by 79.49% to -$258.1 million in 2024, then surged by 59.12% to -$105.5 million in 2025, then jumped by 4342.56% to $4.5 billion in 2026.
• The last three Retained Earnings figures came in at $4.5 billion (Q1 2026), -$105.5 million (Q4 2025), and -$102.3 million (Q3 2025), per Business Quant data.